Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment and prevention of seizures in preeclampsia/eclampsia,Management of acute hypomagnesemia,Treatment of life-threatening ventricular arrhythmias (e.g., torsade de pointes),Off-label: acute asthma exacerbation, tetanus, and constipation
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Magnesium sulfate is primarily excreted unchanged by the kidneys. It does not undergo significant hepatic metabolism.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Approximately 30–40% bound to albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.2–0.3 L/kg. Distributes mainly in extracellular fluid; crosses placenta and blood-brain barrier.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100%. IM: ~80% (variable). Oral: <20% (poor, due to limited absorption; primarily used for catharsis).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR <20 m L/min: maximum dose 2 g; avoid use if anuria. GFR 20-50 m L/min: reduce dose by 25-50%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class B or C: reduce dose by 50% and monitor serum magnesium levels.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
IV: 20-40 mg/kg/dose (max 2 g) as 10% solution; for severe hypomagnesemia: 25-50 mg/kg/dose q4-6h.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Reduce initial dose by 25-50%; infuse over longer period; monitor renal function and serum magnesium closely.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Continuous infusion of magnesium sulfate can cause hypermagnesemia, which may lead to respiratory depression or cardiac arrest. Only use with continuous monitoring of serum magnesium levels and clinical status.
None.
Risk of hypermagnesemia, especially in renal impairment; monitor serum magnesium levels, deep tendon reflexes, and respiratory rate; use with caution in patients with myasthenia gravis or heart block; avoid extravasation due to risk of tissue necrosis.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to magnesium sulfate; heart block or myocardial damage; severe renal impairment (anuria or oliguria); hypermagnesemia.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, high dietary magnesium intake from supplements or foods may increase risk of toxicity when receiving magnesium sulfate. Maintain adequate hydration.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with standard short-term use. Third trimester: risk of neonatal hypotonia, respiratory depression if given near delivery. Continuous infusion for tocolysis >48 hours increases risk of neonatal bone abnormalities.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Magnesium is excreted into breast milk; estimated infant dose approximately 1-2% of maternal weight-adjusted dose. M/P ratio not established. Risk of infant diarrhea and hypotonia with high maternal doses. Avoid prolonged high-dose therapy during breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Increased renal clearance in pregnancy may necessitate higher doses to maintain therapeutic magnesium levels. Monitor serum magnesium levels closely and adjust infusion rate accordingly (usual loading dose 4-6 g IV, maintenance 1-2 g/h). In preeclampsia/eclampsia, target serum magnesium 4-7 m Eq/L.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Magnesium sulfate is first-line for eclampsia and severe preeclampsia. Monitor for loss of deep tendon reflexes (DTRs) as early sign of toxicity; DTRs disappear at ~10 m Eq/L serum magnesium. Calcium gluconate is the antidote for magnesium toxicity. Use with caution in renal impairment; dose adjustment recommended. IV administration can cause hypotension and bradycardia. Not compatible with solutions containing calcium; may precipitate.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any muscle weakness, difficulty breathing, or extreme drowsiness immediately.,You may experience warmth, flushing, or sweating during IV infusion.,Avoid driving or operating heavy machinery until effects are known.,Inform your doctor if you have kidney disease, heart block, or are taking other medications.,Use during pregnancy is typically under close monitoring; discuss risks and benefits.,Do not suddenly stop taking magnesium sulfate; follow prescribed tapering schedule.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Felbamate, an antiepileptic drug, potentiates the central nervous system (CNS) depressant effects of magnesium sulfate, a tocolytic and anticonvulsant agent. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired motor coordination. Clinically, concurrent use may exacerbate hypotonia, hyporeflexia, and somnolence, particularly in patients with renal impairment or those receiving high doses."
"Coadministration of Clevidipine, a dihydropyridine calcium channel blocker, and Magnesium sulfate, which acts as a physiological calcium antagonist, potentiates the hypotensive and negative inotropic effects due to additive inhibition of calcium influx into cardiac and vascular smooth muscle cells. This can lead to exaggerated reductions in blood pressure, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Severe hypotension and heart block have been reported, especially during intravenous administration of both agents."
"The combination of nicardipine, a calcium channel blocker, and magnesium sulfate, a calcium antagonist, synergistically reduces vascular smooth muscle contractility and myocardial conduction. This additive pharmacodynamic effect can lead to profound hypotension, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Clinically, patients may experience symptomatic hypotension, dizziness, or syncope, and in severe cases, cardiovascular collapse may occur."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM SULFATE IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
MAGNESIUM SULFATE IN PLASTIC CONTAINER is a Electrolyte that works by Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM SULFATE IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM SULFATE IN PLASTIC CONTAINER is: IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM SULFATE IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM SULFATE IN PLASTIC CONTAINER is classified as Category C. Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.